Friday, 16 October 2026European Markets

NHOA Stock Went Down By Over 21% In The Last 10 Sessions

Loading stream...

(vianews) - shares of nhoa (cac 40: nhoa.pa) dropped by a staggering 21.94% in 10 sessions from €4.74 to €3.70 at 17:06 est on monday, after two consecutive sessions in a row of losses. cac 40 is falling 0.99% to €7,315.84, following the last session's upward trend.

nhoa's last close was €3.72, 73.54% under its 52-week high of €14.06.

about nhoa

nhoa s.a. provides energy storage, e-mobility, and ev fastcharging infrastructure related solutions in france. the company offers solar plus storage, utility-scale storage, and industrial microgrids. it also provides charging services and devices for electric and hybrid vehicles. in addition, the company offers power house, and hybrid house; and hyess, a technology platform for the transformation of renewables into sustainable grids, as well as atlante, an estation that provides fast charging solution. nhoa s.a. is based in paris, france.

earnings per share

as for profitability, nhoa has a trailing twelve months eps of €-1.49.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -58.43%.

volume

today's last reported volume for nhoa is 14651 which is 48.51% below its average volume of 20883.

volatility

nhoa's last week, last month's, and last quarter's current intraday variation average was a negative 7.14%, a positive 0.85%, and a positive 4.19%.

nhoa's highest amplitude of average volatility was 7.59% (last week), 5.26% (last month), and 4.19% (last quarter).

revenue growth

year-on-year quarterly revenue growth grew by 262.7%, now sitting on 165.69m for the twelve trailing months.

more news about nhoa (nhoa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com